Learn more about lung cancer at YouAndLungCancer.com
This animation provides an overview of immunotherapy for non-small cell lung cancer (NSCLC) with PD-1 and PD-L1 biomarkers. The option of immunotherapy is one more reason why everyone diagnosed with NSCLC should have biomarker testing. Watch to learn about PD-1, PD-L1, and CTLA-4 checkpoint proteins, and the different immune checkpoint inhibitor drugs that act on PD-1, PD-L1, and CTLA-4. You can also learn about finding a clinical trial if you have PD-1, PD-L1, or CTLA-4.
- Understanding Immunotherapy for NSCLC with PD-1 and PD-L1 Biomarkers ( Download)
- Explaining Immunotherapy, PD-L1 and PD-1 ( Download)
- Immunotherapy: Moving beyond PD1 and PDL1 inhibitors ( Download)
- Immunotherapy in Oncology and the Role of the PD-L1 Biomarker ( Download)
- Dr. Lilenbaum on PD-L1 as a Predictive Biomarker for Immunotherapy in Lung Cancer ( Download)
- Cancer Immunotherapy - PD-1 and PD-L1 ( Download)
- Cancer immunotherapy | The PD-L1 pathway ( Download)
- The role of PD-L1: is it accurate enough as a biomarker for immunotherapy response ( Download)
- Dr. Costa on Biomarkers Beyond PD-L1 for Immunotherapy in NSCLC ( Download)
- Understanding Immunotherapy for Lung Cancer ( Download)
- PD-L1 Expression in NSCLC ( Download)
- How does PD-L1 impact treatment options for lung cancer ( Download)
- Dr. Gandara Discusses PD-L1 as a Biomarker in Lung Cancer ( Download)
- Immune checkpoint inhibitors: recent progress and potential biomarkers - 3i PD-L1 Overexpression ( Download)
- Immune checkpoint inhibitors: recent progress and potential biomarkers - 3iv PD-L1 Overexpression ( Download)
